The effects of rasagiline on cognitive deficits in Parkinson's disease patients without dementia: A randomized, double-blind, placebo-controlled, multicenter study

Hasmet A. Hanagasi

doi:10.1002/mds.26235

The effects of rasagiline on cognitive deficits in Parkinson's disease patients without dementia: A randomized, double-blind, placebo-controlled, multicenter study

Movement Disorders ◽

10.1002/mds.26235 ◽

2015 ◽

Vol 30 (7) ◽

pp. 1009-1009

Author(s):

Hasmet A. Hanagasi

Keyword(s):

Parkinson’S Disease ◽

Parkinson's Disease ◽

Cognitive Deficits ◽

Multicenter Study ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

The effects of rasagiline on cognitive deficits in Parkinson's disease patients without dementia: A randomized, double-blind, placebo-controlled, multicenter study

Movement Disorders ◽

10.1002/mds.23738 ◽

2011 ◽

Vol 26 (10) ◽

pp. 1851-1858 ◽

Cited By ~ 51

Author(s):

Hasmet A. Hanagasi ◽

Hakan Gurvit ◽

Pınar Unsalan ◽

Hilal Horozoglu ◽

Nese Tuncer ◽

...

Keyword(s):

Parkinson’S Disease ◽

Parkinson's Disease ◽

Cognitive Deficits ◽

Multicenter Study ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Efficacy and safety of rasagiline monotherapy in Japanese patients with early Parkinson’s disease: A phase 3, randomized, double-blind, placebo-controlled, multicenter study

Journal of the Neurological Sciences ◽

10.1016/j.jns.2017.08.662 ◽

2017 ◽

Vol 381 ◽

pp. 231-232 ◽

Cited By ~ 1

Author(s):

N. Hattori ◽

A. Takeda ◽

S. Takeda ◽

A. Nishimura ◽

T. Kitagawa ◽

...

Keyword(s):

Parkinson’S Disease ◽

Parkinson's Disease ◽

Multicenter Study ◽

Japanese Patients ◽

Efficacy And Safety ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Early Parkinson’S Disease

Download Full-text

Topiramate as an adjunct to amantadine in the treatment of dyskinesia in parkinson's disease: A randomized, double-blind, placebo-controlled multicenter study

Movement Disorders ◽

10.1002/mds.27092 ◽

2017 ◽

Vol 32 (9) ◽

pp. 1335-1336 ◽

Cited By ~ 7

Author(s):

Christopher G. Goetz ◽

Glenn T. Stebbins ◽

Kathryn A. Chung ◽

Anthony P. Nicholas ◽

Robert A. Hauser ◽

...

Keyword(s):

Parkinson’S Disease ◽

Parkinson's Disease ◽

Multicenter Study ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Efficacy and safety of adjunctive rasagiline in Japanese Parkinson's disease patients with wearing-off phenomena: A phase 2/3, randomized, double-blind, placebo-controlled, multicenter study

Parkinsonism & Related Disorders ◽

10.1016/j.parkreldis.2018.04.025 ◽

2018 ◽

Vol 53 ◽

pp. 21-27 ◽

Cited By ~ 4

Author(s):

Nobutaka Hattori ◽

Atsushi Takeda ◽

Shinichi Takeda ◽

Akira Nishimura ◽

Masafumi Kato ◽

...

Keyword(s):

Parkinson’S Disease ◽

Parkinson's Disease ◽

Multicenter Study ◽

Phase 2 ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Wearing Off

Download Full-text

Faculty Opinions recommendation of Apomorphine sublingual film for off episodes in Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.737065221.793569342 ◽

2020 ◽

Author(s):

Joseph Jankovic ◽

Arjun Tarakad

Keyword(s):

Parkinson’S Disease ◽

Parkinson's Disease ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Faculty Opinions recommendation of Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.8286956.8718054 ◽

2011 ◽

Author(s):

Irene Litvan ◽

Rita Simoes

Keyword(s):

Parkinson’S Disease ◽

Parkinson's Disease ◽

Depressive Symptoms ◽

Controlled Trial ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Faculty Opinions recommendation of Memantine for patients with Parkinson's disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.8638956.9139058 ◽

2011 ◽

Cited By ~ 1

Author(s):

John O'Brien ◽

John-Paul Taylor

Keyword(s):

Parkinson’S Disease ◽

Parkinson's Disease ◽

Dementia With Lewy Bodies ◽

Controlled Trial ◽

Lewy Bodies ◽

Parkinson’S Disease Dementia ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Pingchan granule for depressive symptoms in parkinson’s disease: A randomized, double-blind, placebo-controlled trial

Journal of Integrative Medicine ◽

10.1016/j.joim.2020.12.006 ◽

2020 ◽

Author(s):

Si-chun Gu ◽

Jie Zhou ◽

Qing Ye ◽

Can-xing Yuan

Keyword(s):

Parkinson’S Disease ◽

Parkinson's Disease ◽

Depressive Symptoms ◽

Controlled Trial ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

P1-067: AMBROXOL AS PHARMACOLOGICAL CHAPERONE TARGETING GBA1 AS A DISEASE MODIFYING TREATMENT FOR PARKINSON'S DISEASE DEMENTIA: A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL

Alzheimer s & Dementia ◽

10.1016/j.jalz.2018.06.069 ◽

2006 ◽

Vol 14 (7S_Part_5) ◽

pp. P296-P296

Author(s):

Stephen H. Pasternak ◽

Carolina Silveira ◽

Zhonghan Li ◽

Robert Bartha ◽

Michael Borrie ◽

...

Keyword(s):

Parkinson’S Disease ◽

Parkinson's Disease ◽

Controlled Trial ◽

Phase 2 ◽

Parkinson’S Disease Dementia ◽

Double Blind ◽

Pharmacological Chaperone ◽

Double Blind Placebo ◽

Disease Modifying ◽

Disease Modifying Treatment

Download Full-text

P2.098 Saflnamide as an adjunct to levodopa signiflcantly improved motor fluctuations in Parkinson's disease: a phase III, randomized, double-blind, placebo-controlled study

Parkinsonism & Related Disorders ◽

10.1016/s1353-8020(09)70449-3 ◽

2009 ◽

Vol 15 ◽

pp. S115

Author(s):

R. Borgohain ◽

J. Szasz ◽

M. Bhatt ◽

S. Rossetti ◽

V. Lucini ◽

...

Keyword(s):

Parkinson’S Disease ◽

Parkinson's Disease ◽

Motor Fluctuations ◽

Phase Iii ◽

Controlled Study ◽

Double Blind ◽

Double Blind Placebo

Download Full-text